Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Medinet Commercializes Dendritic Cell Engineering Technology Developed By U.S. Biotech

This article was originally published in PharmAsia News

Executive Summary

Yokohama, Japan-based biomedical company Medinet Aug. 18 began commercializing a dendritic cell engineering technology. Utilizing cell loading technology jointly developed with Gaithersburg, Md.-based MaxCyte, the new approach to cancer immunotherapy is expected to increase efficacy as much as 10 times compared to what Medinet is currently providing. As an immune cell therapy, the efficacy of dendritic cell vaccine therapy is improved when it can take up tumor antigens prepared from the patient's removed tumor, thus inducing more cytotoxic T lymphocytes to attack the patient's tumor cells. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts